Back to Main Website

Global Health Impact Map

Global Health Impact Map


Anti-Influenza Hyperimmune Intravenous Immunoglobulin Clinical Outcome (IVIG)

Key Contact: Dr. James D. Neaton | Visit Activity Website

Country(ies): Argentina, Australia, Denmark, Germany, Greece, Spain, Thailand, United Kingdom, United States


Contact Information

2221 University Avenue SE Room 200 Minneapolis MN 55414
Work Phone: 612-626-9040
Work Email: neato001@umn.edu

Activity Description

INSIGHT 006, the Anti-Influenza Hyperimmune Intravenous Immunoglobulin Clinical Outcome Study (FLU-IVIG), is an international randomized double-blind placebo-controlled trial of anti-influenza hyperimmune intravenous immunoglobulin (IVIG) in individuals hospitalized with influenza (flu) A or B, to determine whether, when added to standard of care (SOC) treatment, IVIG helps reduce the severity and duration of flu symptoms. FLU-IVIG is expected to enroll approximatedly 320 participants at up to 40 sites in the US, Europe, South America, and Australasia. Each participant is followed for approximately 28 days. The study is expected to enroll over multiple flu seasons in both the Northern and Southern Hemispheres.

Activity Types

Research

Academic Health Center Units

School of Public Health
     Biostatistics

Other Collaborators

Leidos Biomedical Research

Partner Organizations

Institute for Clinical Research at VA Medical Center, MRC at University College London, University of New South Wales, CHIP at University of Denmark Hospital

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Activity Topics

Influenza

Status

Current